Our Partners

Inhibitor rates related to treatment product in previously untreated patients: Statement from the WFH

An international study of risk factors for inhibitors in children with severe hemophilia A appears to have identified a difference in inhibitor rates between different types of clotting factor concentrates.An increased risk of inhibitor development was observed in previously untreated patients (PUPs) using a second generation recombinant product as compared to a third generation recombinant product.

The researchers are calling for further evaluation and confirmation in a second study. Click here to read full statement.